147 related articles for article (PubMed ID: 37993890)
1. Economic evaluations of immunization programs as an indispensable tool for policymakers.
den Boon S; Ahmed S; Sarker AR
BMC Health Serv Res; 2023 Nov; 23(1):1284. PubMed ID: 37993890
[TBL] [Abstract][Full Text] [Related]
2. A guideline for economic evaluations of vaccines and immunization programs in China.
Fang H; Chen C; Fang Y; He X; Hou Z; Jiang M; Jiang Y; Li S; Liu Y; Sui B; Sun Q; Wu J; Xu T; Yang J; Yin Z; Ying X; Yuan B; Zheng H; Zheng Y
Hum Vaccin Immunother; 2022 Nov; 18(6):2132802. PubMed ID: 36287462
[TBL] [Abstract][Full Text] [Related]
3. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of economic evaluations of vaccination programs in mainland China: Are they sufficient to inform decision making?
Pan XF; Griffiths UK; Pennington M; Yu H; Jit M
Vaccine; 2015 Nov; 33(46):6164-72. PubMed ID: 26435189
[TBL] [Abstract][Full Text] [Related]
5. Considering economic analyses in the revision of the preventive vaccination law: a new direction for health policy-making in Japan?
Akazawa M; Yongue J; Ikeda S; Satoh T
Health Policy; 2014 Oct; 118(1):127-34. PubMed ID: 25139708
[TBL] [Abstract][Full Text] [Related]
6. National decision-making for the introduction of new vaccines: A systematic review, 2010-2020.
Donadel M; Panero MS; Ametewee L; Shefer AM
Vaccine; 2021 Apr; 39(14):1897-1909. PubMed ID: 33750592
[TBL] [Abstract][Full Text] [Related]
7. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR.
Sevilla JP; Bloom DE; Cadarette D; Jit M; Lipsitch M
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):12911-12919. PubMed ID: 30559203
[TBL] [Abstract][Full Text] [Related]
8. Evidence-informed vaccine decision making: The introduction of Human Papilloma Virus (HPV) vaccination in the Netherlands.
van der Putten IM; Paulus ATG; Hiligsmann M; Hutubessy RCW; Evers SMAA
Health Policy; 2019 Mar; 123(3):260-266. PubMed ID: 30219371
[TBL] [Abstract][Full Text] [Related]
9. Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study.
van der Putten IM; Evers SM; Deogaonkar R; Jit M; Hutubessy RC
BMC Public Health; 2015 Apr; 15():356. PubMed ID: 25881178
[TBL] [Abstract][Full Text] [Related]
10. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules.
Miller MA; McCann L
Health Econ; 2000 Jan; 9(1):19-35. PubMed ID: 10694757
[TBL] [Abstract][Full Text] [Related]
11. Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella.
Doggen K; van Hoek AJ; Luyten J
Pharmacoeconomics; 2023 May; 41(5):481-497. PubMed ID: 36809673
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
13. 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study.
Wang J; Wang Y; Xu R; Zhang T; Jiang Y; Wang Y; Wang Y; Du Y; Sun W; Deng K; Yang W; Wang Z; Feng L; Wang C
Infect Dis Poverty; 2023 Dec; 12(1):110. PubMed ID: 38037092
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review.
Getchell M; Mantaring EJ; Yee K; Pronyk P
Vaccine; 2023 Mar; 41(14):2320-2328. PubMed ID: 36781333
[TBL] [Abstract][Full Text] [Related]
15. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines.
Brinsmead R; Hill S; Walker D
Pediatr Infect Dis J; 2004 Jan; 23(1):32-7. PubMed ID: 14743043
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination.
Ng SS; Hutubessy R; Chaiyakunapruk N
Vaccine; 2018 May; 36(19):2529-2544. PubMed ID: 29625764
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
20. School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program.
Basurto-Dávila R; Meltzer MI; Mills DA; Beeler Asay GR; Cho BH; Graitcer SB; Dube NL; Thompson MG; Patel SA; Peasah SK; Ferdinands JM; Gargiullo P; Messonnier M; Shay DK
Health Serv Res; 2017 Dec; 52 Suppl 2(Suppl 2):2307-2330. PubMed ID: 29130266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
